Dassault Systèmes stock gets Medidata trial-design recognition

Medidata, a Dassault Systèmes brand, received the "Real World Evidence Solution of the Year" award on Tuesday, November 10, 2026. The recognition adds a new business detail ahead of Dassault Systèmes' Capital Markets Day on November 17.

According to GlobeNewswire, Medidata's Synthetic Control Arm was selected in the sixth annual BioTech Breakthrough Awards from 1,500 entries. The product is designed to create external control groups for clinical trials, either replacing or supplementing traditional randomized control arms.

AI supports external trial controls

The platform uses aggregated and anonymized data from more than 42,000 clinical trials and 13 million patients, applying propensity-score modelling to match trial populations. Medidata said the approach can help sponsors evaluate therapies when recruiting a conventional control group is difficult, including in rare diseases.

The announcement cited a hybrid Phase 3 design with Medicenna that reduced the required randomized control arm by 66 percent. It also cited work with Autolus to contextualize a single-arm Phase 2 trial for Aucatzyl. These examples indicate a focus on regulatory and trial-design applications rather than a new financial target for Dassault Systèmes.

Next milestone is strategic update

Dassault Systèmes stock traded at 25.38 euros on Lang & Schwarz at 17:07 CET on Tuesday, November 10, 2026.

Dassault Systèmes stock facts

• Company: Dassault Systèmes
• ISIN: FR0014003TT8
• Ticker: DSY.PA
• Lang & Schwarz price: 25.38 euros at 17:07 CET on November 10, 2026
• Brand: Medidata

The CAC 40 provides the relevant French market backdrop for investors.

Dassault Systèmes is scheduled to hold its Capital Markets Day on Tuesday, November 17, 2026. More news and analyses on Dassault Systèmes stock.